

Protein kinase C zeta plays an important role in the oncogenic phenotype of pancreatic cancer cells

Amanda M. Butler, Michele L. Scotti, Shuhua Li, Alan P. Fields and Nicole R. Murray
 Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL

ABSTRACT:

Pancreatic cancer remains the fourth leading cause of cancer deaths in the United States due, in part, to its propensity for invasion and metastasis. Protein kinase C zeta (PKC ζ) has been shown to regulate migration and invasion of both normal and malignant cell types. PKC ζ has been shown to play a pro-carcinogenic role in various cancer types, including breast, colon, and glioblastoma; however, a role for PKC ζ in the transformed growth of pancreatic cancer has not been demonstrated. We hypothesized that PKC ζ may contribute to the lethality of pancreatic cancer by promoting cancer cell invasion and metastasis. Consistent with the hypothesis that PKC ζ plays a role in the pancreatic cancer phenotype, PKC ζ is overexpressed in a subset of human pancreatic tumors compared to associated non-tumor pancreas tissue. In the present study we use RNAi-mediated inhibition of PKC ζ expression to investigate the role of PKC ζ in the growth and invasion of pancreatic cancer cells. Inhibition of PKC ζ reduces log phase growth and survival of human pancreatic cancer cell lines, with a corresponding reduction in colony formation in soft agar. Inhibition of PKC ζ significantly reduces the size of tumors formed by human pancreatic cancer cells in a mouse orthotopic tumor model. Analysis of the isolated orthotopic tumors reveals a reduction in tumor cell proliferation in PKC ζ RNAi tumors. In addition, PKC ζ RNAi tumors exhibit elevated tumor necrosis compared to non-target RNAi (control) tumors. Furthermore, PKC ζ RNAi tumors produce fewer metastases to distal organs, corresponding to the reduced migration and invasion of PKC ζ RNAi cells *in vitro*. Signal transducer and activator of transcription 3 (STAT3), which is often constitutively activated in pancreatic tumors and pancreatic cancer cell lines, has been implicated in pancreatic cancer cell survival and metastasis. Indeed, we observe reduced cell survival, migration and invasion in pancreatic cancer cells in which STAT3 signaling is inhibited. Interestingly, inhibition of PKC ζ significantly reduces constitutive STAT3 phosphorylation in pancreatic cancer cells *in vitro* and *in vivo*. Taken together these data strongly support a required role for PKC ζ in pancreatic cancer cell survival, migration and invasion, and indicate that STAT3 may be a downstream effector of PKC ζ in pancreatic cancer.




Figure 1. PKC ζ is elevated in a subset of human pancreatic tumors.
 A) PKC ζ expression is significantly increased in a subset of tumors compared with matched non-tumor tissue. Quantitative PCR analysis of PKC ζ mRNA expression was performed on 28 matched patient pancreatic tumor and non-tumor samples. PKC ζ expression was normalized to 18S abundance. B) Quantitation of A). C) PKC ζ expression is significantly elevated in a subset of pancreatic tumors.




Figure 2. Inhibition of PKC ζ expression reduces survival and transformed growth of pancreatic cancer cells.
 Panc-1 cells were infected with lentiviral constructs expressing either control, non-targeting (NT) or PKC ζ -targeting RNAi (z1 and z2) and stable populations selected with puromycin. A) Immunoblot analysis of PKC ζ , PKC ϵ and β -actin expression (top). qPCR analysis of PKC ζ and PKC ϵ mRNA expression. mRNA abundance is normalized to GAPDH (bottom). Panc-1 NT, z1 and z2 cells were assessed for B) cell growth (MTT colorimetric assay); C) basal cellular apoptosis by DNA break ELISA and D) anchorage-independent growth by soft agar colony formation. For each panel Bars=average of 6 or more replicates \pm SD and graph is representative of 3 or more independent experiments.




Figure 3. Inhibition of PKC ζ expression significantly reduces orthotopic pancreatic tumor size and tumor metastasis.
 A) Representative bioluminescent imaging of mice with orthotopic Panc-1 NT and PKC ζ RNAi pancreatic tumors. B) Weight of pancreas containing Panc-1 NT and PKC ζ RNAi tumors. Quantitative analysis of tumor C) BrdU incorporation and D) cleaved caspase-3. E) Quantitative analysis of tumor necrosis (left). Representative H&E stained orthotopic Panc-1 NT and PKC ζ RNAi pancreatic tumors with areas of necrosis identified (right, yellow outline). F) Mice with Panc-1 PKC ζ RNAi orthotopic tumors developed significantly less metastases than mice with Panc-1 NT RNAi orthotopic tumors. n=15 NT RNAi tumors and 16 PKC ζ RNAi tumors for all analyses in this figure.




Figure 4. PKC ζ expression regulates Panc-1 migration and invasion.
 A) Cellular migration was assessed in Panc-1 NT and PKC ζ RNAi cells (top) and Panc-1 vector-control and PKC ζ over-expressing cells (bottom) in a real time cell migration assay. B) Cellular invasion through Matrigel-coated chambers was assessed in Panc-1 NT and PKC ζ RNAi cells (top) and Panc-1 vector-control and PKC ζ over-expressing cells (bottom).




Figure 5. Inhibition of PKC ζ expression significantly reduces STAT3 pY705 and STAT3 inhibition reduces Panc-1 migration and invasion.
 A) Inhibition of PKC ζ expression decreases constitutive pSTAT3 (Y705). Immunoblot analysis was performed on total cell lysates from Panc-1 NT and PKC ζ RNAi cells (left). Quantitation of immunoblot (right). B) Representative IHC of pSTAT3 (Y705) in orthotopic Panc-1 NT and PKC ζ RNAi pancreatic tumors (left). Quantitative analysis of pSTAT3 (Y705) IHC staining (right). C) Cellular migration was assessed in Panc-1 cells treated with STAT3 inhibitor (S3I-201, 100 μ M) or control (DMSO) in a Real time cell migration assay. D) Cellular invasion through Matrigel-coated chambers was assessed in Panc-1 cells treated with STAT3 inhibitor (S3I-201, 100 μ M) or control (DMSO).

CONCLUSIONS:

Our results demonstrate a requirement for PKC ζ in the transformed growth in Panc-1 pancreatic cancer cells *in vitro* and *in vivo*. Our data demonstrate a role for PKC ζ and STAT3 in Panc1invasion and migration. Our data suggest that PKC ζ regulates STAT3 activation in pancreatic cancer cells. Taken together, our data implicate PKC ζ as a candidate therapeutic target for the treatment of pancreatic cancer.

ACKNOWLEDGEMENTS:

We thank Brandy Edenfield of the Mayo Clinic Cancer Basic Science Histology Resource for excellent technical assistance. We acknowledge the Mayo Clinic SPOR in Pancreatic Cancer Patient Registry and Tissue Core (supported by P50 CA102701 (Gloria Petersen, PI) and the Lustgarten Foundation for Pancreatic Cancer Research) for providing the biospecimens used in this study. Funding for this study provided by: R03 CA143164 (N.R. Murray), Daniel Foundation of Alabama Postdoctoral Fellowship (M.L. Scotti), F31 CA168117-01 (A.M. Butler) and The Mayo Clinic Foundation.